Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Lupin Ltd.
NSE: LUPIN
|
BSE: 500257
|
ISIN: INE326A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Strong Performer, Getting Expensive
2274.5000
-0.40
(
-0.02
%)
NSE
Apr 02, 2026
15:31 PM
Near 52W High of ₹2377.60
Volume:
1.2M
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Lupin Ltd.
16 Feb 2026
US FDA Approval
2274.50
-0.02%
Result Update:Lupin
Buy:
Lupin Ltd.
by
Axis Direct
Target: 2460 | Upside : 8.2%
Target
Axis Direct
We recommend a BUY rating with a target price of Rs 2,460/share.
Lupin Ltd. is trading
below its 30 day SMA
of 2297.4
More from Lupin Ltd.
Recommended
Five Interesting Stocks Today - April 2, 2026
The Baseline |
02 Apr 2026, 06:00PM
Market closes higher on strong rupee and value buying
Trendlyne Marketwatch |
02 Apr 2026, 03:59PM
Lupin expects normalization by September quarter
|
17 Apr 2020